Asset Details
Do you wish to reserve the book?
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Do you wish to request the book?
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
2005
Overview
In animal models, cannabinoid-1 receptor (CB
1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB
1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients.
patients with body-mass index 30 kg/m
2 or greater, or body-mass index greater than 27 kg/m
2 with treated or untreated dyslipidaemia, hypertension, or both, were randomised to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The primary efficacy endpoint was weight change from baseline after 1 year of treatment in the intention-to-treat population.
Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean −3·4 kg [SD 5·7]; p=0·002
vs placebo) and 20 mg (−6·6 kg [7·2]; p<0·001 vs placebo) compared with placebo (−1·8 kg [6·4]). Significantly more patients treated with rimonabant 20 mg than placebo achieved weight loss of 5% or greater (p<0·001) and 10% or greater (p<0·001). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome. The effects of rimonabant 5 mg were of less clinical significance. Rimonabant was generally well tolerated with mild and transient side effects.
CB
1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.
Publisher
Elsevier Ltd,Elsevier Limited,Elsevier
Subject
/ Cardiovascular Diseases - etiology
/ Cardiovascular Diseases - prevention & control
/ Cardiovascular Diseases/etiology/prevention & control
/ Diet
/ Endocrinologie, métabolisme & nutrition
/ Endocrinology, metabolism & nutrition
/ Female
/ Humans
/ Male
/ Obesity
/ Obesity, Morbid - drug therapy
/ Obesity/complications/drug therapy/metabolism
/ Pharmacie, pharmacologie & toxicologie
/ Pharmacy, pharmacology & toxicology
/ Piperidines - adverse effects
/ Piperidines - therapeutic use
/ Piperidines/adverse effects/therapeutic use
/ Pyrazoles/adverse effects/therapeutic use
/ Receptor, Cannabinoid, CB1 - antagonists & inhibitors
